Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease.

TitleSex differences in the genetic architecture of cognitive resilience to Alzheimer's disease.
Publication TypeJournal Article
Year of Publication2022
AuthorsEissman JM, Dumitrescu L, Mahoney ER, Smith AN, Mukherjee S, Lee ML, Scollard P, Choi SEun, Bush WS, Engelman CD, Lu Q, Fardo DW, Trittschuh EH, Mez J, Kaczorowski CC, Saucedo HHernandez, Widaman KF, Buckley RF, Properzi MJ, Mormino EC, Yang HSik, Harrison TM, Hedden T, Nho K, Andrews SJ, Tommet D, Hadad N, R Sanders E, Ruderfer DM, Gifford KA, Zhong X, Raghavan NS, Vardarajan BN, Pericak-Vance MA, Farrer LA, San Wang L, Cruchaga C, Schellenberg GD, Cox NJ, Haines JL, C Keene D, Saykin AJ, Larson EB, Sperling RA, Mayeux R, Cuccaro ML, Bennett DA, Schneider JA, Crane PK, Jefferson AL, Hohman TJ
Corporate AuthorsAlzheimer’s Disease Neuroimaging Initiative(ADNI), Alzheimer’s Disease Genetics Consortium(ADGC), A4 Study Team
JournalBrain
Volume145
Issue7
Pagination2541-2554
Date Published07/2022
ISSN1460-2156
KeywordsAlzheimer Disease, Cognition, Cognitive Dysfunction, Female, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Male, Multiple Sclerosis, Sex Characteristics
Abstract

Approximately 30% of elderly adults are cognitively unimpaired at time of death despite the presence of Alzheimer's disease neuropathology at autopsy. Studying individuals who are resilient to the cognitive consequences of Alzheimer's disease neuropathology may uncover novel therapeutic targets to treat Alzheimer's disease. It is well established that there are sex differences in response to Alzheimer's disease pathology, and growing evidence suggests that genetic factors may contribute to these differences. Taken together, we sought to elucidate sex-specific genetic drivers of resilience. We extended our recent large scale genomic analysis of resilience in which we harmonized cognitive data across four cohorts of cognitive ageing, in vivo amyloid PET across two cohorts, and autopsy measures of amyloid neuritic plaque burden across two cohorts. These data were leveraged to build robust, continuous resilience phenotypes. With these phenotypes, we performed sex-stratified [n (males) = 2093, n (females) = 2931] and sex-interaction [n (both sexes) = 5024] genome-wide association studies (GWAS), gene and pathway-based tests, and genetic correlation analyses to clarify the variants, genes and molecular pathways that relate to resilience in a sex-specific manner. Estimated among cognitively normal individuals of both sexes, resilience was 20-25% heritable, and when estimated in either sex among cognitively normal individuals, resilience was 15-44% heritable. In our GWAS, we identified a female-specific locus on chromosome 10 [rs827389, β (females) = 0.08, P (females) = 5.76 × 10-09, β (males) = -0.01, P(males) = 0.70, β (interaction) = 0.09, P (interaction) = 1.01 × 10-04] in which the minor allele was associated with higher resilience scores among females. This locus is located within chromatin loops that interact with promoters of genes involved in RNA processing, including GATA3. Finally, our genetic correlation analyses revealed shared genetic architecture between resilience phenotypes and other complex traits, including a female-specific association with frontotemporal dementia and male-specific associations with heart rate variability traits. We also observed opposing associations between sexes for multiple sclerosis, such that more resilient females had a lower genetic susceptibility to multiple sclerosis, and more resilient males had a higher genetic susceptibility to multiple sclerosis. Overall, we identified sex differences in the genetic architecture of resilience, identified a female-specific resilience locus and highlighted numerous sex-specific molecular pathways that may underly resilience to Alzheimer's disease pathology. This study illustrates the need to conduct sex-aware genomic analyses to identify novel targets that are unidentified in sex-agnostic models. Our findings support the theory that the most successful treatment for an individual with Alzheimer's disease may be personalized based on their biological sex and genetic context.

DOI10.1093/brain/awac177
Alternate JournalBrain
PubMed ID35552371
PubMed Central IDPMC9337804
Grant ListP50 MH084051 / MH / NIMH NIH HHS / United States
U01 AG006781 / AG / NIA NIH HHS / United States
R01 AG061518 / AG / NIA NIH HHS / United States
P30 AG019610 / AG / NIA NIH HHS / United States
K23 AG062750 / AG / NIA NIH HHS / United States
K24 AG046373 / AG / NIA NIH HHS / United States
U01 AG006786 / AG / NIA NIH HHS / United States
R01 AG015819 / AG / NIA NIH HHS / United States
R21 AG059941 / AG / NIA NIH HHS / United States
P20 AG068082 / AG / NIA NIH HHS / United States
U24 AG074855 / AG / NIA NIH HHS / United States
P50 AG016574 / AG / NIA NIH HHS / United States
R01 MH093725 / MH / NIMH NIH HHS / United States
R56 AG057191 / AG / NIA NIH HHS / United States
P50 MH096891 / MH / NIMH NIH HHS / United States
R01 AG018023 / AG / NIA NIH HHS / United States
R01 AG073439 / AG / NIA NIH HHS / United States
R01 NS100980 / NS / NINDS NIH HHS / United States
RF1 AG051550 / AG / NIA NIH HHS / United States
T32 GM080178 / GM / NIGMS NIH HHS / United States
R01 AG032990 / AG / NIA NIH HHS / United States
R37 MH057881 / MH / NIMH NIH HHS / United States
U01 AG068057 / AG / NIA NIH HHS / United States
P50 MH066392 / MH / NIMH NIH HHS / United States
U01 AG032984 / AG / NIA NIH HHS / United States
P01 AG002219 / AG / NIA NIH HHS / United States
U01 AG046139 / AG / NIA NIH HHS / United States
R01 MH085542 / MH / NIMH NIH HHS / United States
U01 AG061356 / AG / NIA NIH HHS / United States
R01 MH110921 / MH / NIMH NIH HHS / United States
P01 AG017216 / AG / NIA NIH HHS / United States
U01 AG024904 / AG / NIA NIH HHS / United States
F31 AG051381 / AG / NIA NIH HHS / United States
P50 AG005136 / AG / NIA NIH HHS / United States
R13 AG030995 / AG / NIA NIH HHS / United States
R01 MH109677 / MH / NIMH NIH HHS / United States
U19 AG066567 / AG / NIA NIH HHS / United States
R01 NS080820 / NS / NINDS NIH HHS / United States
R01 MH075916 / MH / NIMH NIH HHS / United States
R01 MH097276 / MH / NIMH NIH HHS / United States
R01 AG074012 / AG / NIA NIH HHS / United States
U01 MH103392 / MH / NIMH NIH HHS / United States
U24 AG041689 / AG / NIA NIH HHS / United States
R01 AG056534 / AG / NIA NIH HHS / United States
R01 AG057914 / AG / NIA NIH HHS / United States
R00 AG061238 / AG / NIA NIH HHS / United States
S10 OD023680 / OD / NIH HHS / United States
P30 AG072975 / AG / NIA NIH HHS / United States
HHSN271201300031C / DA / NIDA NIH HHS / United States
P30 AG066509 / AG / NIA NIH HHS / United States
P30 AG010161 / AG / NIA NIH HHS / United States
U01 AG046152 / AG / NIA NIH HHS / United States
U24 NS072026 / NS / NINDS NIH HHS / United States
R01 AG046171 / AG / NIA NIH HHS / United States
K12 HD043483 / HD / NICHD NIH HHS / United States
P50 MH084053 / MH / NIMH NIH HHS / United States
R01 AG034962 / AG / NIA NIH HHS / United States
R01 MH109897 / MH / NIMH NIH HHS / United States
K01 AG049164 / AG / NIA NIH HHS / United States
R01 AG059716 / AG / NIA NIH HHS / United States
UL1 TR000445 / TR / NCATS NIH HHS / United States
R01 AG017917 / AG / NIA NIH HHS / United States